Pyridone-containing phenalenone-based photosensitizer working both under light and in the dark for photodynamic therapy

Bioorg Med Chem. 2019 Jun 1;27(11):2201-2208. doi: 10.1016/j.bmc.2019.04.023. Epub 2019 Apr 17.

Abstract

Photosensitizer attracts great attentions and has potential applications in cancer treatment. We developed here a novel pyridone-containing phenalenone-based (PPN-PYR) photosensitizer with excellent singlet oxygen generating ability. Upon light irradiation, PPN-PYR can produce singlet oxygen and transform to its endoperoxide form which in turn release singlet oxygen via thermal cycloreversion at dark. The ability of PPN-PYR to generate reactive oxygen species (ROS) in cell culture and induce corresponding apoptosis both at dark and under light was demonstrated. The efficient PDT performance of PPN-PYR was further verified on cancer cell in vitro. Our study indicate that PPN-PYR can alleviate tumor hypoxia problem and enhance the availability of intermittent photodynamic therapy.

Keywords: 2-Pyridone; Cytotoxicity; Endoperoxide; Phenylphenalenone; Photosensitizer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / radiation effects
  • Apoptosis / drug effects
  • Drug Stability
  • HeLa Cells
  • Humans
  • Light
  • Phenalenes / chemical synthesis
  • Phenalenes / pharmacology*
  • Phenalenes / radiation effects
  • Photochemotherapy / methods
  • Photosensitizing Agents / chemical synthesis
  • Photosensitizing Agents / pharmacology*
  • Photosensitizing Agents / radiation effects
  • Proof of Concept Study
  • Pyridones / chemical synthesis
  • Pyridones / pharmacology*
  • Pyridones / radiation effects
  • Singlet Oxygen / metabolism

Substances

  • Antineoplastic Agents
  • Phenalenes
  • Photosensitizing Agents
  • Pyridones
  • Singlet Oxygen
  • phenalen-1-one